A nanomedicine approach enables co-delivery of cyclosporin A and gefitinib to potentiate the therapeutic efficacy in drug-resistant lung cancer

Drug resistance, accounting for therapeutic failure in the clinic, remains a major challenge to effectively manage cancer. Cyclosporin A (CsA) can reverse multidrug resistance (MDR), especially resistance to epidermal growth factor receptor tyrosine kinase inhibitors. However, the application of bot...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Weidong, Shi, Linlin, Ren, Lulu, Zhou, Liqian, Li, Tongyu, Qiao, Yiting, Wang, Hangxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6013461/
https://www.ncbi.nlm.nih.gov/pubmed/29942660
http://dx.doi.org/10.1038/s41392-018-0019-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6013461/
https://www.ncbi.nlm.nih.gov/pubmed/29942660
http://dx.doi.org/10.1038/s41392-018-0019-4

Ejemplares similares